Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL0911 in Pediatric Chronic Primary Immune Thrombocytopenia
NCT07455006Phase 3Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing QL0911 Arm with Placebo Arm (2 arms). Primary endpoint: Percentage of Participants With a Durable Platelet Response. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
QL0911
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07455006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07455006.